(Q35209305)

English

Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safety

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

1 reference

Europe PubMed Central

Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safety (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

author name string

Christie M Ballantyne

1

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

language of work or name

0 references

publication date

1 August 2003

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

92

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

4B

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

3K-9K

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900768-9

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900768-9

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900768-9

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900768-9

7 January 2021

Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900768-9

7 January 2021

Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900768-9

7 January 2021

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900768-9

7 January 2021

Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900768-9

7 January 2021

Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900768-9

7 January 2021

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900768-9

7 January 2021

Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900768-9

7 January 2021

Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900768-9

7 January 2021

Rosuvastatin--a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900768-9

7 January 2021

Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900768-9

7 January 2021

Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900768-9

7 January 2021

Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900768-9

7 January 2021

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900768-9

7 January 2021

Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900768-9

7 January 2021

Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900768-9

7 January 2021

Identifiers

10.1016/S0002-9149(03)00768-9

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35209305&oldid=1608919626"